Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275392285> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2275392285 endingPage "6045" @default.
- W2275392285 startingPage "6045" @default.
- W2275392285 abstract "6045 Background: Advanced cancer patients (ACP) in phase I clinical trials are unable to recall many important elements of IC, yet the content of discussion between physician-investigators (PI) and ACP consenting to such trials has not been well described. Methods: Clinical encounters were recorded between 131 ACP entering phase I trials and 25 PIs at three institutions (University of Chicago; Johns Hopkins; and Duke University). ACP completed follow-up questionnaires 1 week later to assess understanding of IC elements, e.g., research purpose of phase I trials. Recordings were analyzed using the Roter Interaction Analysis System (RIAS), and coding for terms associated with IC elements. Results: To date, 87 ACP-PI encounters have been analyzed. Average length of encounters: 30.4 min (range: 5.7-77.8 min). ACP demographics include: median age 60y (33-83); 55% female; 88% Ca; 55% < $60,000. PIs were coded as stating: 1) The purpose of a phase I trial as determining dosage/toxicity in 40% of encounters; 2) Physical risk of a trial in 70% of the encounters; 3) Life-threatening risks in 10% of the encounters; 4) Potential benefits gained by subject participation in the trial related to improvement in quality of life or stabilization of disease in 63% of encounters; and 5) Trial alternatives in 58% of the encounters. Within follow-up interviews, 26% of ACP described the purpose of a phase I trial as determining drug safety; 67% described alternatives to trial participation. An association existedbetween coding for PI statements re: the purpose of a phase I trial as dosage/toxicity and ACP correctly recalling the purpose of the trial (86% vs. 14%, p < 0.05). Conclusions: PI communication and subsequent ACP understanding of important elements of IC remain inadequate in the phase I trial setting. No significant financial relationships to disclose." @default.
- W2275392285 created "2016-06-24" @default.
- W2275392285 creator A5003940631 @default.
- W2275392285 creator A5025048434 @default.
- W2275392285 creator A5036024184 @default.
- W2275392285 creator A5050109359 @default.
- W2275392285 creator A5054484886 @default.
- W2275392285 creator A5063967284 @default.
- W2275392285 creator A5068268371 @default.
- W2275392285 creator A5075918212 @default.
- W2275392285 date "2010-05-20" @default.
- W2275392285 modified "2023-09-25" @default.
- W2275392285 title "Communication of the essential elements of informed consent (IC) for research: A RIAS analysis of phase I clinical trial encounters." @default.
- W2275392285 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.6045" @default.
- W2275392285 hasPublicationYear "2010" @default.
- W2275392285 type Work @default.
- W2275392285 sameAs 2275392285 @default.
- W2275392285 citedByCount "0" @default.
- W2275392285 crossrefType "journal-article" @default.
- W2275392285 hasAuthorship W2275392285A5003940631 @default.
- W2275392285 hasAuthorship W2275392285A5025048434 @default.
- W2275392285 hasAuthorship W2275392285A5036024184 @default.
- W2275392285 hasAuthorship W2275392285A5050109359 @default.
- W2275392285 hasAuthorship W2275392285A5054484886 @default.
- W2275392285 hasAuthorship W2275392285A5063967284 @default.
- W2275392285 hasAuthorship W2275392285A5068268371 @default.
- W2275392285 hasAuthorship W2275392285A5075918212 @default.
- W2275392285 hasConcept C126322002 @default.
- W2275392285 hasConcept C142724271 @default.
- W2275392285 hasConcept C144024400 @default.
- W2275392285 hasConcept C149923435 @default.
- W2275392285 hasConcept C159110408 @default.
- W2275392285 hasConcept C204787440 @default.
- W2275392285 hasConcept C2779951463 @default.
- W2275392285 hasConcept C2780084366 @default.
- W2275392285 hasConcept C31760486 @default.
- W2275392285 hasConcept C512399662 @default.
- W2275392285 hasConcept C535046627 @default.
- W2275392285 hasConcept C68122502 @default.
- W2275392285 hasConcept C71924100 @default.
- W2275392285 hasConcept C74909509 @default.
- W2275392285 hasConceptScore W2275392285C126322002 @default.
- W2275392285 hasConceptScore W2275392285C142724271 @default.
- W2275392285 hasConceptScore W2275392285C144024400 @default.
- W2275392285 hasConceptScore W2275392285C149923435 @default.
- W2275392285 hasConceptScore W2275392285C159110408 @default.
- W2275392285 hasConceptScore W2275392285C204787440 @default.
- W2275392285 hasConceptScore W2275392285C2779951463 @default.
- W2275392285 hasConceptScore W2275392285C2780084366 @default.
- W2275392285 hasConceptScore W2275392285C31760486 @default.
- W2275392285 hasConceptScore W2275392285C512399662 @default.
- W2275392285 hasConceptScore W2275392285C535046627 @default.
- W2275392285 hasConceptScore W2275392285C68122502 @default.
- W2275392285 hasConceptScore W2275392285C71924100 @default.
- W2275392285 hasConceptScore W2275392285C74909509 @default.
- W2275392285 hasIssue "15_suppl" @default.
- W2275392285 hasLocation W22753922851 @default.
- W2275392285 hasOpenAccess W2275392285 @default.
- W2275392285 hasPrimaryLocation W22753922851 @default.
- W2275392285 hasRelatedWork W1964708144 @default.
- W2275392285 hasRelatedWork W1976641068 @default.
- W2275392285 hasRelatedWork W1985812505 @default.
- W2275392285 hasRelatedWork W2019868776 @default.
- W2275392285 hasRelatedWork W2060304500 @default.
- W2275392285 hasRelatedWork W2108624693 @default.
- W2275392285 hasRelatedWork W2137636999 @default.
- W2275392285 hasRelatedWork W2166174961 @default.
- W2275392285 hasRelatedWork W2391885877 @default.
- W2275392285 hasRelatedWork W2901073114 @default.
- W2275392285 hasVolume "28" @default.
- W2275392285 isParatext "false" @default.
- W2275392285 isRetracted "false" @default.
- W2275392285 magId "2275392285" @default.
- W2275392285 workType "article" @default.